Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by Crossref.
Robinson, M. B.
Thompson, E.
and
Black, N. A.
1998.
Why is evaluation of the cost effectiveness of audit so difficult? The example of thrombolysis for suspected acute myocardial infarction.
Quality and Safety in Health Care,
Vol. 7,
Issue. 1,
p.
19.
Hoomans, Ties
Evers, Silvia M.A.A.
Ament, André J.H.A.
Hübben, Mariette W.A.
van der Weijden, Trudy
Grimshaw, Jeremy M.
and
Severens, Johan L.
2007.
The Methodological Quality of Economic Evaluations of Guideline Implementation into Clinical Practice: A Systematic Review of Empiric Studies.
Value in Health,
Vol. 10,
Issue. 4,
p.
305.
Kleintjens, Joris
Li, Xiao
Simoens, Steven
Thijs, Vincent
Goethals, Marnix
Rietzschel, Ernst R.
Asukai, Yumi
Saka, Ömer
Evers, Thomas
Faes, Petra
Vansieleghem, Stefaan
and
De Ruyck, Mimi
2013.
Cost-Effectiveness of Rivaroxaban Versus Warfarin for Stroke Prevention in Atrial Fibrillation in the Belgian Healthcare Setting.
PharmacoEconomics,
Vol. 31,
Issue. 10,
p.
909.
Rubio-Terrés, Carlos
Graefenhain de Codes, Ruth
Rubio-Rodríguez, Darío
Evers, Thomas
and
Grau Cerrato, Santiago
2016.
Cost-effectiveness Analysis of Rivaroxaban versus Acenocoumarol in the Prevention of Stroke in Patients with Non-valvular Atrial Fibrillation in Spain.
Journal of Health Economics and Outcomes Research,
Vol. 4,
Issue. 1,
p.
19.
Moore, Lynne
Guertin, Jason Robert
Tardif, Pier-Alexandre
Ivers, Noah Michael
Hoch, Jeffrey
Conombo, Blanchard
Antony, Jesmin
Stelfox, Henry Thomas
Berthelot, Simon
Archambault, Patrick
Turgeon, Alexis
Gandhi, Rohit
and
Grimshaw, JM
2022.
Economic evaluations of audit and feedback interventions: a systematic review.
BMJ Quality & Safety,
Vol. 31,
Issue. 10,
p.
754.